-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is one of the leading causes of tumor-related deaths worldwide.
lung adenocarcinoma (LUAD) as the main histological type of lung cancer, the incidence of LUAD in China increased year by year.
, although new treatments for LUAD have been developed, the five-year survival rate is only 12 to 15 per cent.
, further exploration of LUAD molecular mechanisms and identification of corresponding biomarkers can improve the effectiveness of patients.
previous studies have shown that non-coded RNA (ncRNA) plays a vital role in all types of cancer.
ring RNA (circRNA) as a unique class of non-coding RNA, in mammalian cells and tissues have unique characteristics and functions.
circRNA plays a regulatory role in a variety of diseases, including cancer, and performs the function of the well-known "miRNA molecular sponge".
, there is very little research on non-coding RNA in genomic-altering regions, especially circRNA.
earlier in the study, through RNA sequencing, showed an increase in the expression levels of some circRNAs in LUAD tumor tissue.
transcripts of circXPO1 have discovered a new circRNA, circXPO1, in LUAD from a recognized cancer treatment target, XPO1.
circXPO1 is formed by reverse shearing of the XPO1 gene's exons 3 and exons 4.
, circXPO1 was expressed higher in LUAD tissue than in adjacent non-tumor tissues, while the high expression level of circXPO1 was associated with a worse overall survival rate.
found that the level of expression of circXPO1 was positively related to the number of copies of the XPO1 gene.
mechanism studies have shown that circXPO1 can bind to IGF2BP1 and enhance the stability of CTNNB1 mRNA, and ultimately promote the development of LUAD.
in transplant tumor models derived from LUAD patients, the injection of specific target circXPO1 cholesterol-adorned siRNA in tumors can effectively inhibit tumor growth.
results show that circXPO1 is critical to the development of LUAD and may act as a biomarker for adverse prognosmation and treatment of luad tumors, as described in the study.
。
